Rheoscience, Dr. Reddy's Move Balaglitazone Into Phase III Trial

Sheridan, Cormac
August 2007
BioWorld International;8/8/2007, Vol. 12 Issue 32, p1
This article reports on the Phase III clinical trial of balaglitazone, a partial agonist of peroxisome proliferator-activated receptor gamma, in patients with Type II diabetes, which is being conducted by Rheoscience A/S and Dr. Reddy's Laboratories Ltd. Balaglitazone is a member of the thiazolidinedione class of insulin sensitizers. The objective of the study is to demonstrate non-inferiority of balaglitazone as compared with Actos, a drug marketed by Takeda Pharmaceutical Co.


Related Articles

  • Dr. Reddy's Balaglitazone Data Solid in Phase III.  // Bioworld Week;1/11/2010, Vol. 18 Issue 2, p2 

    The article reports on the solid top-line data gathered by pharmaceutical companies Dr. Reddy's Laboratories Ltd. and Nordic Bioscience AS from the Phase III trial of the insulin sensitizer balaglitazone. It presents findings for the efficacy of Takeda Pharmaceuticals Co. Ltd.'s Actos in dodging...

  • Takeda Publishes TAK-875 Data.  // Drug Discovery & Development;Apr2012, Vol. 15 Issue 4, p26 

    The article reports on the publication of the phase 2 clinical data from Pharmaceutical Co. Ltd. in 2012 for its TAK-875 type 2 diabetes therapy.

  • ADA 2011.  // BioWorld Today;6/29/2011, Vol. 22 Issue 125, p9 

    The article focuses on data presented by Takeda Pharmaceutical Co. Ltd. at the 2011 American Diabetes Association meeting from a Phase II trial evaluating the efficacy, safety and tolerability of once-daily treatment with TAK-875 in Type II diabetes patients.

  • 'Reddy' for Another PPAR Drug? Balaglitazone Solid in Phase III. Osborne, Randy // BioWorld International;1/6/2010, Vol. 15 Issue 1, p3 

    The article reports on the positive findings of the first phase III trial of Dr. Reddy's Laboratories Ltd. and Nordic Bioscience A/S for balaglitazone, a peroxisome proliferator-activated receptor (PPAR)-agonist for diabetes. The trial has revealed that balaglitazone was able to avoid the bad...

  • Pipeline.  // Pharmaceutical Representative;Nov2011, Vol. 41 Issue 11, p10 

    The article offers information on several pharmaceutical companies. It mentions that Takeda Pharmaceutical Co. Ltd., announced the Phase III clinical trial program for TAK-875, an investigational therapy for type 2 diabetes. It states that interim antiviral response and safety data were issued...

  • FDA Dings the Takeda/Furiex Type II Diabetes Combo. Shaffer, Catherine // BioWorld International;5/2/2012, Vol. 17 Issue 18, p4 

    This article reports on the May 2012 response letter by the U.S. Food and Drug Administration (FDA) to Takeda Pharmaceutical Co. Ltd. of Osaka, Japan regarding new drug applications for alogliptin and fixed-dose combinations of alogliptin and pioglitazone developed by the company and Furiex...

  • Clinic Roundup.  // BioWorld Today;9/6/2011, Vol. 22 Issue 172, p3 

    The article reports on a randomized, double-blind, placebo-controlled Phase II trial of DRL-17822, initiated by Dr. Reddy's Laboratories Ltd. in Type II diabetes.

  • Pharma: Clinic Roundup.  // BioWorld Today;2/22/2012, Vol. 23 Issue 35, p11 

    The article reports on the results of the GEMINI I Phase III trial of vedolizumab conducted by Takeda Pharmaceutical Co. Ltd.

  • Pharma: Clinic Roundup.  // BioWorld Today;5/14/2012, Vol. 23 Issue 93, p6 

    The article focuses on the positive results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal Phase III trial, reported by Takeda Pharmaceuticals Co. Ltd.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics